Daewoong Pharmaceutical announced a strategic partnership with global informatics platform company Revvity Signals to accelerate the digital transformation of its drug development research systems.

The collaboration aims to digitize Daewoong’s drug development systems, reducing decision-making time by approximately 45 percent and lowering experimental data error rates by around 75 percent through automated data recording. The approach is expected to significantly shorten drug development timelines.

As part of the agreement, Revvity Signals will provide Daewoong with software and technologies critical for research system digitalization and data visualization. Key tools include ChemDraw, Signals Notebook, and Spotfire, which facilitate compound structure design, digital storage and management of experimental data, and integrated analysis and reporting of research findings.

Daewoong plans to integrate these technologies into its proprietary digital platform, the DWP Discovery Portal, and its electronic research notebooks. Beyond mere adoption, Daewoong intends to customize and enhance the software to create a uniquely tailored system, further advancing its drug discovery capabilities.

Launched in April 2023, Daewoong’s DWP Discovery Portal is an advanced digital platform for drug discovery. It digitizes the Design-Make-Test-Analyze (DMTA) cycle, a core process in drug discovery, supporting data-driven decision-making and improving research productivity.

The upgraded system will enable systematic data collection, meaningful insights through data visualization, and data-driven decision-making, ultimately increasing R&D efficiency and accelerating drug development processes.

Meanwhile, Daewoong has demonstrated its R&D prowess with back-to-back approvals of first-in-class Korean drugs, such as Fexuclue for gastroesophageal reflux disease and Envlo for type 2 diabetes, over the past two years.

Through this partnership, Daewoong aims to further enhance its R&D competitiveness and accelerate the development of global blockbuster drugs.

“Daewoong has been actively building diverse digital research systems to enhance productivity in drug development while forging partnerships with innovative technology companies,” Daewoong Chief of Drug Discovery Center Park Joon-seok said. “Through this agreement, we aim to accelerate digital transformation, enhance research efficiency, and further expand our drug development pipeline.”

Revvity Signals APAC Business Leader Charles J. Coyne also said, “This partnership provides comprehensive digital solutions for Daewoong’s drug development efforts.”

The company looks forward to our leading technologies contributing to Daewoong’s innovative pipeline, Coyne added.